SNY Overview
Upcoming Projects (SNY)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (SNY)
-
Discussing BTK inhibitors in autoimmune indications
Tickers: NVS, BMY, GILD, SNY
Executed On: Oct 01, 2024 at 01:30 PM EDT -
Evaluating the Phase 3 HERCULES Study Results for Tolebrutinib in Non-Relapsing Secondary Progressive Multiple Sclerosis from Sanofi
Ticker: SNY
Executed On: Sep 06, 2024 at 09:30 AM EDT -
Exploring Sanofi's BTK inhibitor Rilzabrutinib for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP)
Ticker: SNY
Executed On: May 22, 2024 at 04:00 PM EDT -
Examining the results from the phase 2b STREAM-AD clinical trial of amlitelimab for atopic dermatitis presented at EADV 2023.
Ticker: SNY
Executed On: Nov 28, 2023 at 02:30 PM EST -
Discussing Regeneron & Sanofi's newly approved Kevzara® (sarilumab) in treating Polymyalgia Rheumatica (PMR)
Tickers: REGN, SNY
Executed On: Aug 31, 2023 at 09:00 AM EDT -
Discussing the potential use of Sanofi and AstraZeneca’s newly approved RSV antibody drug for infants, nirsevimab, with a Pediatric Allergist
Tickers: SNY, AZN
Executed On: Jul 19, 2023 at 06:30 PM EDT -
A look at enzyme replacement therapies in Pompe disease including Sanofi's Nexviazyme and Amicus Therapeutics' Pombiliti + Opfolda (AT-GAA)
Tickers: FOLD, SNY
Executed On: Jul 17, 2023 at 05:00 PM EDT -
Examining the potential of Sanofi's novel anti-CD40L antibody, frexalimab, in patients with relapsing multiple sclerosis with a neurologist
Ticker: SNY
Executed On: Jun 27, 2023 at 12:30 PM EDT -
Discussing the treatment landscape for hemophilia A with a focus on Biomarin's Roctavian (Valoctocogene Roxaparvovec) & Sanofi's Altuviiio (efanesoctocog alfa)
Tickers: BMRN, SNY
Executed On: Mar 08, 2023 at 02:00 PM EST -
Getting an endocrinologist's view on Rezvoglar and other available interchangeable biosimilar insulin products in managing diabetes
Tickers: LLY, VTRSV, SNY
Executed On: Jan 05, 2023 at 04:30 PM EST -
A Second View: Getting an endocrinologist's view on Rezvoglar and other available interchangeable biosimilar insulin products in managing diabetes
Tickers: LLY, SNY, VTRSV
Executed On: Jan 05, 2023 at 01:30 PM EST -
Discussing the trends in the NK cell landscape for the future of CART therapies, specifically FATE therapeutics and their iPSC-Derived cell products
Tickers: FATE, SNY
Executed On: Dec 16, 2022 at 09:00 AM EST -
Discussing the use and potential of Rezurock for the treatment of Chronic Graft vs. Host disease (cGVHD)
Ticker: SNY
Executed On: Mar 02, 2022 at 06:00 PM EST
Expired Projects (SNY)
-
Discussing the potential of Sanofi/Regeneron FDA approved therapy, Kevzara (sarilumab), in Polymyalgia rheumatica (PMR)
Tickers: SNY, REGN
Execute By: May 31, 2023 -
Examining the potential of Sanofi's factor VIII replacement therapy, efanesoctocog alfa (BIVV001) in severe hemophilia A
Ticker: SNY
Execute By: Nov 22, 2022 -
Evaluating the Multiple Sclerosis Market After AbbVie (ABBV) and Biogen (BIIB) Receive CHMP Support for EU Approval of Zinbryta
Tickers: ABBV, BIIB, TEVA, NVS, SNY, MedDay Pharmaceuticals, RHHBY
Execute By: May 23, 2016 -
Evaluating the Market Potential of Hua Medicine's HMS5552 in Type II Diabetes Ahead of Mid-Year Phase II Readout. Does the drug have potential to derail the success of major players in the space?
Tickers: HUA MEDICINE, ABT, AZN, NVS, NVO, MRK, SNY, GSK, Lupin Pharmaceuticals, RHHBY
Execute By: May 11, 2016
Upcoming & Overdue Catalysts (SNY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (SNY)
-
EU in talks with Moderna, BioNtech, Sanofi, Johnson & Johnson and CureVac to secure possible COVID vaccines
Tickers: JNJ, SNY, BNTX, MRNA
Occurred on: Jul 17, 2020 -
PDUFA date for Dupixent (dupilumab) in Nasal polyps under priority review June 26, 2019
Tickers: REGN, SNY
Occurred on: Jun 26, 2019 -
Phase 3 Results for Dupixent (dupilumab) in Adolescents with Moderate-to-Severe Atopic Dermatitis Presented at the 27th EADV Congress
Tickers: REGN, SNY
Occurred on: Sep 15, 2018 -
Phase 2 Study Results for Regeneron's(REGN) Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis Released
Tickers: REGN, SNY
Occurred on: Oct 16, 2017 -
FDA Decision Expected By April 5th for Merck's (MRK) Glargine (MK-1293) in Type 1 and Type 2 Diabetes
Tickers: MRK, SNY, LLY, NVO
Occurred on: Jul 20, 2017 -
Regeneron (REGN) and Sanofi (SNY) rheumatoid arthritis drug Kevzara (sarilumab) granted FDA approval
Tickers: REGN, SNY
Occurred on: May 22, 2017 -
PDUFA Date of March 29, 2017 Set for Regeneron (REGN) and Sanofi's (SNY) Dupilumab in Treatment of Atopic Dermatitis
Tickers: REGN, SNY
Occurred on: Mar 28, 2017 -
Sanofi (SNY) and Regeneron (REGN) Announce U.S Lawsuit Against Amgen (AMGN) Over Patent for Asthma Drug
Tickers: AMGN, REGN, SNY
Occurred on: Mar 21, 2017 -
Sanofi's (SNY) Over-the-Counter Allergy Med Xyzal Approved by FDA
Ticker: SNY
Occurred on: Feb 01, 2017 -
Regeneron (REGN) and Sanofi's (SNY) Sarilumab Approved in Canada for Adult Patients with Moderately to Severely Active Rheumatoid Arthritis (RA)
Tickers: SNY, REGN
Occurred on: Feb 01, 2017 -
Final Decision Expected from European Commission in ~60 Days on Sanofi's (SNY) Suliqua in Type 2 Diabetes
Ticker: SNY
Occurred on: Jan 18, 2017 -
Delaware District Court Denies Sanofi (SNY) and Regeneron's (REGN) Motion to Stay the Injunction in PCSK9 Patent Dispute with Amgen (AMGN)
Tickers: REGN, AMGN, SNY
Occurred on: Jan 09, 2017 -
FDA decision for Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide anticipated in November 2016
Ticker: SNY
Occurred on: Nov 21, 2016 -
Sanofi (SNY) Receives FDA Approval of Soliqua 100/33, for the Treatment of Adults with Type 2 Diabetes
Ticker: SNY
Occurred on: Nov 21, 2016 -
First Patient Enrolled in Phase 3 COMET Study Evaluating Sanofi's (SNY) NeoGAA in Treatment of Pompe Disease
Ticker: SNY
Occurred on: Nov 17, 2016 -
Regeneron (REGN) and Sanofi (SNY) to Present Data from Phase 3 Praluent (alirocumab) Injection Clinical Trials at AHA Scientific Sessions 2016
Tickers: REGN, SNY
Occurred on: Nov 12, 2016 -
Regeneron (REGN) and Sanofi's (SNY) Sarilumab for Rheumatoid Arthritis Granted PDUFA date of October 30, 2016 by FDA
Tickers: REGN, JNJ, SNY, GSK
Occurred on: Oct 28, 2016 -
Regeneron (REGN) and Sanofi's (SNY) Biologics License Application for Dupilumab in Atopic Dermatitis (AD) Accepted for Priority Review by FDA
Tickers: REGN, SNY
Occurred on: Sep 26, 2016 -
GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) Plan to Submit Application to FDA in 2016 for Sirukumab in Rheumatoid Arthritis
Tickers: GSK, REGN, SNY, JNJ
Occurred on: Sep 23, 2016 -
GlaxoSmithKline (GSK) and Johnson & Johnson (JNJ) Submit Sirukumab in Treatment of Rheumatoid Arthritis to European Medicines Agency
Tickers: GSK, JNJ, SNY, REGN
Occurred on: Sep 12, 2016 -
Sanofi Genzyme Begins Pivotal Phase 2/3 Trial of Olipudase Alfa for Adult Patients with Acid Sphingomyelinase Deficiency
Ticker: SNY
Occurred on: Jul 06, 2016 -
Approval of Praluent (Alirocumab) For The Treatment Of Hypercholesterolemia In Japan
Ticker: SNY
Occurred on: Jul 05, 2016 -
New Four-Strain Influenza Vaccine, VaxigripTetra, Regulatory Dossier from Sanofi Pasteur Now Approved in Europe
Ticker: SNY
Occurred on: Jun 23, 2016 -
Merus Labs acquire the rights to Surgestone, Provames, Speciafoldine, and Tredemine in France from Sanofi
Tickers: SNY, MSLI
Occurred on: Feb 23, 2016 -
FDA Accepts Sanofi (SNY) New Drug Application for Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
Ticker: SNY
Occurred on: Feb 22, 2016 -
MannKind headed towards bankruptcy despite new partnership with Receptor Life Sciences
Tickers: MNKD, SNY
Occurred on: Jan 27, 2016
Strategic Initiatives (SNY)
-
Regeneron and Sanofi To Accelerate and Expand Investment for Cemiplimab and Dupilumab Development Programs
Tickers: REGN, SNY
Announcement Date: Jan 08, 2018 -
Sanofi (SNY) Announces Non-Exclusive Agreement with Voluntis to Develop Phone Application to Better Manage Type 2 Diabetes Treatment
Tickers: SNY, Voluntis
Announcement Date: Mar 14, 2017 -
Sanofi (SNY) Reaches Global License Agreement to Develop ImmuNext's INX-021 in a Range of Autoimmune Diseases Including Lupus and Multiple Sclerosis
Tickers: SNY, ImmuNext
Announcement Date: Jan 09, 2017 -
Sanofi (SNY) and Alnylam (ALNY) Agree to Co-Develop and Commercialize RNAi Therapeutic Fitusiran in Treatment of Hemophilia and Rare Bleeding Disorders
Tickers: ALNY, SNY
Announcement Date: Nov 14, 2016 -
Sanofi (SNY) Signs Collaboration Deal with Brazilian Fiocruz and the Walter Reed Army Institute of Research (WRAIR) to Accelerate Zika Vaccine Development
Ticker: SNY
Announcement Date: Oct 27, 2016 -
Sanofi Pasteur Signs Research Agreement For Zika Vaccine
Ticker: SNY
Announcement Date: Jul 06, 2016 -
Merck and Sanofi Pasteur end joint vaccine operations in Europe
Tickers: SNY, MRK
Announcement Date: Mar 08, 2016
